Clinical Trials

Clinical Trial Detail

Return to search results.

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Complete title: A Phase 1b/2 Study with Gemcitabine and LY2157299 for Patients with Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)

Research Study Number       20111239
    
Principal Investigator       Andrew Coveler, MD
    
Phase       I/II

Look up trial at NIH

Research Study Description

Phase 1b: To determine the safe and tolerable dose of LY2157299 in combination with gemcitabine in patients with solid malignancy

Phase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of LY2157299 and gemcitabine with that of gemcitabine plus placebo.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.



Research Study Number       20111239
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Gastrointestinal Cancer; Pancreatic Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.